Novel afucosylated anti-B cell maturation antigen-monomethyl auristatin F antibody-drug conjugate (GSK2857916) induces potent and selective anti-multiple myeloma activity.
Tai YT et al. Blood. 2014 Feb 25. [Epub ahead of print].

Bone marrow mast cell density correlates with serum levels of VEGF and CXC chemokines ENA-78 and GRO-α in multiple myeloma.
Pappa CA et al. Tumour Biol. 2014 Feb 23. [Epub ahead of print].

Bone marrow mast cell density correlates with serum levels of VEGF and CXC chemokines ENA-78 and GRO-α in multiple myeloma.
Pappa CA et al. Tumour Biol. 2014 Feb 23. [Epub ahead of print].

A Limited Sampling Model to Estimate Exposure to Lenalidomide in Multiple Myeloma Patients.
Shida S et al. Ther Drug Monit. 2014 Feb 19. [Epub ahead of print].

The detection of risk pathways, regulated by miRNAs, via the integration of sample-matched miRNA-mRNA profiles and pathway structure.
Li J et al. J Biomed Inform. 2014 Feb 20. pii: S1532-0464(14)00040-9. doi: 10.1016/j.jbi.2014.02.004. [Epub ahead of print].

Killing multiple myeloma cells with the small molecule 3-bromopyruvate: implications for therapy.
Majkowska-Skrobek G et al. Anticancer Drugs. 2014 Feb 19. [Epub ahead of print.

PI3K inhibitor LY294002 inhibits activation of the Akt/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma cells to the oncolytic virus.
Tong Y et al. Oncol Rep. 2014 Feb 11. doi: 10.3892/or.2014.3020. [Epub ahead of print].

Curcusone D, a novel ubiquitin-proteasome pathway inhibitor via ROS-induced DUBs inhibition, is synergistic with Bortezomib against multiple myeloma cell growth.
Cao MN et al. Biochim Biophys Acta. 2014 Feb 14. pii: S0304-4165(14)00052-X. doi: 10.1016/j.bbagen.2014.02.006. [Epub ahead of print].

TNF-α-mediated JNK Activation in the Dorsal Root Ganglion Neurons Contributes to Bortezomib-Induced Peripheral Neuropathy.
Zhang J et al. Brain Behav Immun. 2014 Feb 13. pii: S0889-1591(14)00046-4. doi: 10.1016/j.bbi.2014.01.020. [Epub ahead of print].

Genetic variants and multiple myeloma risk: IMMEnSE validation of the best reported associations.
Martino A et al. Cancer Epidemiol Biomarkers Prev. 2014 Feb 12. [Epub ahead of print].

CYP2C19 genotype-phenotype discordance in patients with multiple myeloma leads to an acquired loss of drug-metabolising activity.
Burns KE et al. Cancer Chemother Pharmacol. 2014 Feb 12. [Epub ahead of print].

A novel Bruton’s tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant anti-myeloma activity.
Eda H et al. Leukemia. 2014 Feb 12. doi: 10.1038/leu.2014.69. [Epub ahead of print].

Promiscuous rearrangements of the MYC locus hijack enhancers and super-enhancers to dysregulate MYC expression in multiple myeloma.
Affer M et al. Leukemia. 2014 Feb 12. doi: 10.1038/leu.2014.70. [Epub ahead of print].

Identification of novel fusion genes with 28S ribosomal DNA in hematologic malignancies.
Kobayashi S et al. Int J Oncol. 2014 Apr;44(4):1193-8. doi: 10.3892/ijo.2014.2291. Epub 2014 Feb 5.

Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease.
Sawyer JR et al. Blood. 2014 Feb 4. [Epub ahead of print].

The impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib/dexamethasone therapy.
Sekiguchi N et al. Int J Hematol. 2014 Feb 5. [Epub ahead of print].

Serial exome analysis of disease progression in premalignant gammopathies.
Zhao S et al. Leukemia. 2014 Feb 5. doi: 10.1038/leu.2014.59. [Epub ahead of print].

Preclinical activity of the oral proteasome inhibitor MLN9708 in myeloma bone disease.
Garcia-Gomez A et al. Clin Cancer Res. 2014 Jan 31. [Epub ahead of print].

Gene set enrichment analysis of the NF-κB/Snail/YY1/RKIP circuitry in multiple myeloma.
Zaravinos A et al. Tumour Biol. 2014 Jan 31. [Epub ahead of print].

The use of a neutral peptide aptamer scaffold to anchor BH3 peptides constitutes a viable approach to studying their function.
Stadler LK et al. Cell Death Dis. 2014 Jan 30;5:e1037. doi: 10.1038/cddis.2013.564.

A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib.
Ray A et al. Leukemia. 2014 Jan 30. doi: 10.1038/leu.2014.46. [Epub ahead of print].

8-Hydrocalamenene, Derived from Reynoutria elliptica, Suppresses Constitutive STAT3 Activation, Inhibiting Proliferation and Enhancing Chemosensitization of Human Multiple Myeloma Cells.
Nam D et al. J Med Food. 2014 Jan 29. [Epub ahead of print].

Anti-β2 M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity.
Zhang M et al. Int J Cancer. 2014 Jan 29. doi: 10.1002/ijc.28745. [Epub ahead of print].

Inflammatory Markers and Development of Symptom Burden in Patients with Multiple Myeloma during Autologous Stem Cell Transplantation.
Wang XS et al. Clin Cancer Res. 2014 Feb 11. [Epub ahead of print].

Dinaciclib (SCH727965) Inhibits the Unfolded Protein Response through a CDK1- and 5-Dependent Mechanism.
Nguyen TK et al. Mol Cancer Ther. 2014 Feb 21. [Epub ahead of print].

Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other.
Surget S et al. Leuk Lymphoma. 2014 Feb 17. [Epub ahead of print].

Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.
Mughal TI et al. Leuk Lymphoma. 2014 Feb 17. [Epub ahead of print]